Form 4: Precision Biosciences Director Increases Stake with Recent Stock Purchase

Kevin Buehler, a Director at Precision Biosciences Inc. (DTIL), has acquired 5,076 shares of common stock, increasing his beneficial ownership to 28,137 shares.

Summary

• Kevin Buehler, a Director of Precision Biosciences Inc. (DTIL), purchased 5,076 shares of common stock.
• The transaction occurred on June 25, 2025.
• The shares were acquired at a weighted average price of $4.16 per share, with individual transactions ranging from $4.16 to $4.18.
• Following this transaction, Mr. Buehler beneficially owns a total of 28,137 shares of Precision Biosciences common stock.
• The purchase was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 8

Explanation: The acquisition of shares by a director is a strong positive signal, indicating insider confidence in the company's future performance and valuation.

Positives

• A Director, Kevin Buehler, increased his ownership stake in the company, signaling confidence in the company's future prospects.
• The purchase was made through a Rule 10b5-1(c) plan, which suggests a pre-planned investment decision rather than a reaction to immediate market events.

Future Outlook

NA

Industry Context

This Form 4 filing reflects an individual insider's transaction and does not provide broader industry context or trends. Insider buying can sometimes be seen as a positive signal within the biotechnology industry, indicating confidence from those with intimate knowledge of the company's operations and pipeline.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator of management's belief in the company's value, potentially increasing investor confidence.

Key Dates

Recommendation

Keywords

Precision Biosciences, DTIL, Kevin Buehler, Insider Trading, Form 4, Stock Purchase, Director, Equity Acquisition, Rule 10b5-1